Revelation Biosciences (NASDAQ:REVB) Shares Down 1.9% – Should You Sell?

Revelation Biosciences, Inc. (NASDAQ:REVB)’s stock price dropped 1.9% during mid-day trading on Wednesday . The stock traded as low as $1.02 and last traded at $1.03. Approximately 17,868 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 47,198 shares. The stock had previously closed at $1.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Revelation Biosciences Stock Performance

The company has a market cap of $3.83 million, a price-to-earnings ratio of -0.02 and a beta of -0.09. The stock’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.83.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56). On average, equities research analysts expect that Revelation Biosciences, Inc. will post -4.99 EPS for the current year.

Hedge Funds Weigh In On Revelation Biosciences

A number of hedge funds have recently bought and sold shares of REVB. Sabby Management LLC grew its stake in shares of Revelation Biosciences by 214.7% in the 3rd quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock worth $294,000 after acquiring an additional 141,262 shares in the last quarter. Armistice Capital LLC purchased a new position in Revelation Biosciences during the third quarter worth about $114,000. Finally, Geode Capital Management LLC purchased a new stake in Revelation Biosciences in the 4th quarter valued at about $27,000. 12.80% of the stock is owned by hedge funds and other institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.